Literature DB >> 7527657

Characterization of the inactivation of nitric oxide synthase by NG-methyl-L-arginine: evidence for heme loss.

N M Olken1, Y Osawa, M A Marletta.   

Abstract

The nitric oxide synthases (NOS) are a unique family of P450-type hemoproteins that catalyze the formation of .NO and citrulline from L-arginine, oxygen, and NADPH. NG-Methyl-L-arginine (L-NMA) has been shown to function as a slow, partially uncoupled alternate substrate and mechanism-based inhibitor of the inducible NOS [Olken, N. M., & Marletta, M. A. (1993) Biochemistry 32, 9677-9685]. In this report, the inactivation of NOS by L-NMA has been investigated in detail. Inactivation fails to occur under an argon atmosphere, establishing turnover dependence. The partition ratio, defined as the number of molecules of citrulline formed per NOS monomer inactivated, is 108 +/- 3. By utilizing NG-methyl-L-[2,3-3H2]arginine and NG-[14C]methyl-L-arginine, the stoichiometry of radiolabeling is 0.11 +/- 0.01 equiv of tritium and 0.41 +/- 0.10 equiv of carbon-14 per inactivated NOS monomer. Dialysis under native conditions does not change this stoichiometry. However, dialysis of NOS following denaturation decreases the stoichiometry of radiolabeling to 0.08 +/- 0.04 equiv of tritium and 0.12 +/- 0.04 equiv of carbon-14 per inactivated NOS monomer. Absolute and CO-reduced difference spectroscopy indicates that inactivation of L-NMA is accompanied by a substantial loss of the heme chromophore, which is not prevented by catalase. HPLC analysis of NOS heme following inactivation with L-NMA indicates substantial loss of heme. These findings suggest that multiple mechanisms may contribute to the loss of NOS activity by L-NMA, including heme loss and possibly protein and cofactor modification.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527657     DOI: 10.1021/bi00253a017

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

Review 1.  Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.

Authors:  Xiaohong Liu; Xin Xu; Ruru Shang; Yingjie Chen
Journal:  Nitric Oxide       Date:  2018-06-19       Impact factor: 4.427

Review 2.  Effect of asymmetric dimethylarginine (ADMA) on heart failure development.

Authors:  Xiaoyu Liu; Lei Hou; Dachun Xu; Angela Chen; Liuqing Yang; Yan Zhuang; Yawei Xu; John T Fassett; Yingjie Chen
Journal:  Nitric Oxide       Date:  2016-02-24       Impact factor: 4.427

3.  Dissection, Optimization, and Structural Analysis of a Covalent Irreversible DDAH1 Inhibitor.

Authors:  Gayle Burstein-Teitelbaum; Joyce A V Er; Arthur F Monzingo; Alfred Tuley; Walter Fast
Journal:  Biochemistry       Date:  2018-07-20       Impact factor: 3.162

Review 4.  Inducible nitric oxide synthase: Regulation, structure, and inhibition.

Authors:  Maris A Cinelli; Ha T Do; Galen P Miley; Richard B Silverman
Journal:  Med Res Rev       Date:  2019-06-13       Impact factor: 12.944

5.  Overexpression of neuronal nitric oxide synthase in insect cells reveals requirement of haem for tetrahydrobiopterin binding.

Authors:  B M List; P Klatt; E R Werner; K Schmidt; B Mayer
Journal:  Biochem J       Date:  1996-04-01       Impact factor: 3.857

6.  Beneficial effects of L-arginine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuronal degeneration in substantia nigra of Balb/c mice.

Authors:  Javad Hami; Mehran Hosseini; Saeed Vafaei Nezhad; Sekineh Shahi; Nassim Lotfi; Hossein Ehsani; Akram Sadeghi
Journal:  Adv Biomed Res       Date:  2016-08-30

Review 7.  Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges.

Authors:  Jan Víteček; Antonín Lojek; Giuseppe Valacchi; Lukáš Kubala
Journal:  Mediators Inflamm       Date:  2012-09-04       Impact factor: 4.711

8.  Regulation of DDAH1 as a Potential Therapeutic Target for Treating Cardiovascular Diseases.

Authors:  Xiaoyu Liu; John Fassett; Yidong Wei; Yingjie Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-26       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.